Reviews/ACE Inhibitors and Angiotensin Receptor Blockers/ACE inhibitors and ARBs reduce major adverse cardiovascular events in high cardiovascular risk
CV · ACEARB-CV-01 · v2
Borderline: within 4 points of the Likely/Uncertain boundary, so a re-grade could land either side.
Across many different high-risk groups, people taking these blood-pressure drugs tend to have fewer heart attacks, strokes and deaths than people not taking them. Most of that evidence comes from observational studies that follow patients in real-world care rather than from trials that randomly assign treatment, so some of the apparent benefit could reflect that healthier patients stay on the drugs [14][4][11][26]. The one clean randomized test of an ARB against a dummy pill in exactly these patients did not meet its main goal [3], and the classic placebo trials that originally made the case are not in this collection at all. A head-to-head trial shows the two drug families perform about equally [1], and some subgroups show no benefit or even harm [19][5][20][15]. The panel judged that the consistent real-world signal supports a genuine effect, while the missing trials, the negative result, and the subgroup harms stop it from being treated as settled.
The corpus shows a broad, directionally consistent association between ACEi/ARB use and lower MACE or mortality across varied high-risk populations: post-CABG [14][4], post-SAVR with both classes individually lower [11], peritoneal dialysis [6], maintenance dialysis [8], and a high-vascular-risk registry [27]. Discontinuing these drugs in diabetic advanced CKD was associated with higher MACE (HR 1.27, 95% CI 1.08-1.49) [26], and prolonged ARB exposure in the STEP post hoc analysis was tied to lower cardiovascular risk [13]. ONTARGET establishes that telmisartan was equivalent to ramipril in vascular-disease or high-risk diabetic patients (relative risk 1.01, 95% CI 0.94-1.09) [1]. The strongest randomized evidence directly on the claim, TRANSCEND [3], missed its primary MACE outcome. Contrary primary data appear in ALLHAT [19] and in hypertensive Black patients [5]. The contested point: The division is between a large, consistent observational signal plus supportive head-to-head and post hoc data on one side, and the absence of placebo-controlled landmark trials plus a negative primary endpoint in the one placebo-controlled ARB trial [3] on the other. Whether confounding by indication and healthy-adherer bias inflate the observational benefit, and whether the subgroup harms in [19][5][20][15] undercut the blanket wording 'high-risk patients', are the live points.
All 32 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from ACE Inhibitors and Angiotensin Receptor Blockers, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The single cleanest test in the corpus — the only placebo-controlled ARB trial in high-risk patients, TRANSCEND [3] — was NEGATIVE on its primary MACE outcome (HR 0.92, 95% CI 0.81-1.05, p=0.216). The claimed reduction survives only on a secondary composite that lost statistical significance after adjustment for multiplicity (p=0.068). The strongest randomized evidence therefore argues against a clear primary-endpoint benefit for the ARB arm of the claim.
The corpus contains NO placebo-controlled RCT demonstrating that an ACEi reduces MACE versus placebo in high-risk patients (HOPE, EUROPA, PROGRESS are absent). The ACEi half of the claim rests on observational cohorts ([14][4][11][6][26]) subject to confounding by indication and healthy-adherer bias, where patients kept on therapy are systematically healthier than those who are not.
Where it remains uncertain. The only placebo-controlled ARB trial in these patients, TRANSCEND [3], missed its primary endpoint (HR 0.92, 95% CI 0.81-1.05, p=0.216), and subgroup harm appears in ALLHAT stroke [19] and in hypertensive Black patients [5].
Aleatory
Several key estimates sit near the null boundary, e.g. ANBP2 HR 0.89 (95% CI 0.79-1.00, P=0.05) [2] and the ACCORD-BP emulation HR 0.91 (95% CI 0.63-1.31) [10], so chance plays a real role in where they fall.
Epistemic
The placebo-controlled high-risk ACEi trials that would directly test the claim are not in the corpus, so the ACEi half rests on indirect and observational data [14][4][11].
Inferential
Head-to-head designs [1][10] show the two classes perform similarly; inferring that either reduces events versus no treatment requires an external efficacy assumption the corpus does not test directly.
The load-bearing papers from a corpus of 32, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Establishes ARB non-inferiority to an ACEi in exactly the high-risk population, with ACEi efficacy as the accepted comparator baseline.
“Telmisartan was equivalent to ramipril in patients with vascular disease or high-risk diabetes and was associated with less angioedema.”
Panel auditInternal validity: high · scope of inference: Whether the ARB telmisartan is equivalent to the ACE inhibitor ramipril in patients with vascular disease or high-risk diabetes without heart failure.Key limitations: no placebo arm · active-active comparison only
The only placebo-controlled ARB trial in high-risk patients; primary endpoint NOT significant, capping the strength of the ARB arm of the claim.
“465 (15.7%) patients experienced the primary outcome in the telmisartan group compared with 504 (17.0%) in the placebo group (hazard ratio 0.92, 95% CI 0.81-1.05, p=0.216)”
Panel auditInternal validity: high · scope of inference: Effect of telmisartan on cardiovascular events in high-risk patients intolerant to ACE inhibitors.Key limitations: primary outcome null · secondary benefit borderline after adjustment
Independent registry (SWEDEHEART, N=28,812) associating RAAS inhibition with lower mortality after CABG.
“RAAS inhibitors (HR 0.78, 95% CI 0.73-0.84), and platelet inhibitors (HR 0.74, 95% CI 0.69-0.81) were individually associated with lower mortality risk”
Panel auditInternal validity: low · scope of inference: Association of long-term RAAS inhibitor use with mortality in patients surviving isolated CABG.Key limitations: observational, confounding by indication · outcome is mortality not MACE composite
ACE use was associated with poorer cardiovascular outcomes in blacks and no benefit in whites, contradicting a reduction.
Panel auditInternal validity: low · scope of inference: Comparative effectiveness of ACE-inhibitor-based therapy in hypertensive blacks versus whites in clinical practice.Key limitations: observational · effect differs by race · borderline p values
4 of 32 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The weight of consistent multi-population evidence supports a real class-level MACE reduction, but a negative primary RCT, absent placebo-controlled ACEi trials, confounding in the observational core, and genuine subgroup harm keep it at the lower end of Likely rather than Established.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No placebo-controlled ACEi trial in high-risk patients. The ACEi half of the claim rests entirely on observational cohorts [14][4][11] and a polypill [16]; no trial in the corpus tests an ACEi against placebo for MACE. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomized placebo-controlled trial of an ACEi in high-risk patients with MACE as the primary endpoint, or recovery of the absent landmark trials into the corpus.
Open question: Does an ACEi reduce MACE versus placebo in high-risk patients? Why it is still open: No placebo-controlled ACEi trial exists in the corpus; the ACEi half rests on observational cohorts [14][4][11] and an unisolable polypill [16].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19